Miloš Grujić, Head of Department of the Subspecialist Cabinets at the Center for Radiation Oncology at University Clinical Center Kragujevac, Co-Chair of Career Development Working Group at European School of Oncology, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“Honoured to share our newly published systematic review and meta-analysis in the European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI):
‘Therapeutic outcomes of ²²⁵Ac/¹⁷⁷Lu-PSMA combination therapy in advanced metastatic castration-resistant prostate cancer. Systematic review and meta-analysis’
Grateful to the leading authors Zineddine Belabaci, Giulio Brignoli, and Prof. Thomas Zilli, as well as the entire team of exceptional colleagues from Bern, Switzerland, Jordan, and Germany for guiding this work and driving the field of PSMA-targeted theranostics forward.
A special thank you to Dr. Mohamed Shelan and Zineddine for the invitation to join the project and for their trust, collaboration, and continuous support. It was a privilege to contribute from the perspective of radiation oncology in Serbia.
This review summarizes the current evidence on tandem α/β PSMA radioligand therapy and its potential role for patients with heavily pre-treated mCRPC—an emerging and promising area requiring further prospective evaluations.
Looking forward to future collaborations and continued progress in prostate cancer research and theranostics.”
Title: Therapeutic outcomes of ²²⁵Ac/¹⁷⁷Lu-PSMA combination therapy in advanced metastatic Castration-Resistant prostate cancer: A systematic review and Meta-Analysis
Authors: Zineddine Belabaci, Giulio Brignoli, Thomas Zilli, Miloš Grujić, Issa Mohamad, Akram Al-Ibraheem, Mohamed Shelan, Ali Afshar-Oromieh
Read the Full Article on European Journal of Nuclear Medicine and Molecular Imaging
More posts featuring Miloš Grujić.